Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Drug PIC

MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China

Fineline Cube Sep 4, 2026
Company Deals PIC

Typewriter Therapeutics Raises USD 56 Million Series A to Advance TPRT RNA Gene Insertion Platform for In Vivo CAR-T and Liver Diseases

Fineline Cube Sep 4, 2026
Company Deals Drug PIC

Takeda and Belief BioMed End Xinjiuning Commercialization Partnership; Belief BioMed to Advance Gene Therapy Independently

Fineline Cube Sep 4, 2026
Company Deals Drug PIC

Keymed Biosciences Grants Aeira Exclusive Rights to Stapokibart Across 18 Southeast and Central Asia Markets, Securing High Double‑Digit Royalties

Fineline Cube Sep 3, 2026
Company Deals PIC

Medtronic Invests USD 700 Million in Cornerstone Robotics, Wins Distribution Rights for Sentire Endoscopic Surgical Robot Outside the U.S.

Fineline Cube Sep 3, 2026
Company Drug PIC

MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China

Fineline Cube Sep 4, 2026
Company Drug PIC

MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China

Fineline Cube Sep 4, 2026
Policy / Regulatory

China’s 2026 NHSA Drug Negotiations Open Sept 5 with Parallel Commercial Insurance Innovative Drug Catalog Talks

Fineline Cube Sep 4, 2026
R&D

Oxford and Peking University Study Unveils Genetic Risk Factors in East Asian Population

Fineline Cube Jul 25, 2023

Researchers from the UK’s Oxford Population Health and China’s Peking University have conducted a comprehensive...

Company Deals

Roche and Alnylam Partner on RNAi Therapeutic Zilebesiran for Hypertension Treatment

Fineline Cube Jul 25, 2023

Swiss pharmaceutical giant Roche (SWX: ROG) has signed a deal with US-based RNAi specialist Alnylam...

Company Deals

Pfizer Ends Partnership with Syros Pharmaceuticals for Sickle Cell Disease Program

Fineline Cube Jul 25, 2023

Syros Pharmaceuticals Inc., (NASDAQ: SYRS) has disclosed in an SEC filing that Pfizer (NYSE: PFE)...

Company Drug

Ascletis Pharma’s ASC22 Combo Therapy Shows Promise in HIV Functional Cure Clinical Trial

Fineline Cube Jul 25, 2023

China-based Ascletis Pharma Inc., (HKG: 1672) has announced that the Shanghai Public Health Clinical Center...

Company Drug

Jiangsu Hengrui Pharmaceuticals and Hansoh Pharmaceutical Group Get NMPA Approval for Solid Tumor Treatment

Fineline Cube Jul 25, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received clinical trial...

Company Policy / Regulatory

Taiwan’s TFDA Orders Recall of Two Nucala Batches Due to Glass Fragments

Fineline Cube Jul 25, 2023

The Food and Drug Administration (FDA) bureau of Taiwan, part of Greater China, has issued...

Company Drug

Eli Lilly’s Mirikizumab and Chia Tai Tianqing’s Lanifibranor Enter Breakthrough Therapy Review

Fineline Cube Jul 25, 2023

US pharmaceutical major Eli Lilly’s (NYSE: LLY) mirikizumab and China-based Chia Tai Tianqing’s lanifibranor have...

Company Deals

Amoy Diagnostics and AstraZeneca Expand Partnership for Companion Diagnostic Development

Fineline Cube Jul 25, 2023

China-based Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685) has announced an additional cooperation agreement with...

Company Drug

Vcanbio’s VUM02 Stem Cell Therapy Accepted for Review by China’s CDE for aGvHD Treatment

Fineline Cube Jul 25, 2023

China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that the Center...

Medical Device Policy / Regulatory

NMPA Updates List of Medical Devices Exempt from Clinical Evaluation in China

Fineline Cube Jul 25, 2023

The National Medical Products Administration (NMPA) has released an updated version of the “List of...

Policy / Regulatory

Chinese Health Authorities Unveil Key Reform Tasks for Medical System in H2 2023

Fineline Cube Jul 25, 2023

The National Health Commission (NHC), National Development and Reform Commission (NDRC), Ministry of Finance (MoF),...

Policy / Regulatory

NHSA Releases Official Guidelines for Drug Negotiations and Bidding for NRDL Update

Fineline Cube Jul 24, 2023

The National Healthcare Security Administration (NHSA) has officially released the “Negotiation Drug Renewals” and “Non-exclusive...

Company Deals

Carbon Medical Technology Secures Over RMB 100 Million in Series A Financing for Interventional Therapy

Fineline Cube Jul 24, 2023

Shenzhen-based Carbon Medical Technology Co., Ltd has reportedly raised over RMB 100 million (USD 13.9...

Company Drug

BeiGene’s Tislelizumab Receives Positive CHMP Opinion for Esophageal Cancer Treatment

Fineline Cube Jul 24, 2023

BeiGene (NASDAQ: BGNE) has announced that its programmed death-1 (PD-1) inhibitor, tislelizumab, has received a...

Company Drug

CanSino Biologics Granted Approval by Health Canada for Zoster Vaccine Candidate CS-2032

Fineline Cube Jul 24, 2023

China-based vaccines specialist CanSino Biologics Inc., (HKG: 6185) has announced receiving approval from Health Canada...

Company Deals Drug

Bavarian Nordic’s RSV Vaccine Candidate Fails Phase III Trial, Discontinues Program

Fineline Cube Jul 24, 2023

Denmark-based Bavarian Nordic A/S (CPH: BAVA) has revealed that its pipeline respiratory syncytial virus (RSV)...

Legal / IP Policy / Regulatory

National Health Commission Launches One-Year Anti-Corruption Campaign in Pharmaceutical Sector

Fineline Cube Jul 24, 2023

The emergency response department of the National Health Commission (NHC) has released a notification signaling...

Company

FDA Assures No Disruption to US Drug Supply Chain After Pfizer Warehouse Tornado

Fineline Cube Jul 24, 2023

The US Food and Drug Administration (FDA) has issued a statement this week, ruling out...

Company Deals

Biotherus Inc. and BioNTech SE Enter Global License Agreement for Cancer Therapies

Fineline Cube Jul 21, 2023

China-based biotech company Biotheus Inc. has announced a strategic research collaboration, option, and worldwide license...

Company Drug

Antengene Corp. Receives FDA Fast-Track Designation for Xpovio in Myelofibrosis Treatment

Fineline Cube Jul 21, 2023

China-based biopharma Antengene Corp., Ltd (HKG: 6996) has announced receiving fast-track designation from the US...

Posts pagination

1 … 549 550 551 … 716

Recent updates

  • MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China
  • China’s 2026 NHSA Drug Negotiations Open Sept 5 with Parallel Commercial Insurance Innovative Drug Catalog Talks
  • Trinomab’s Retavibart Wins NMPA Priority Approval as RSV Prevention Monoclonal Antibody Xinduotuo
  • Xuanzhu Biopharmaceutical Signs Thailand Commercial Agreement with Innobic and ZaoAn for Bireociclib
  • Betta’s Ensartinib Wins NMPA Approval for Third Indication as Adjuvant Therapy in ALK-Positive NSCLC
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug PIC

MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China

Policy / Regulatory

China’s 2026 NHSA Drug Negotiations Open Sept 5 with Parallel Commercial Insurance Innovative Drug Catalog Talks

Company Drug

Trinomab’s Retavibart Wins NMPA Priority Approval as RSV Prevention Monoclonal Antibody Xinduotuo

Company Deals

Xuanzhu Biopharmaceutical Signs Thailand Commercial Agreement with Innobic and ZaoAn for Bireociclib

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.